Flagship’s Sigilon grabs $80M to bring Robert Langer cell therapy tech into the clinic
Rogerio Vivaldi had never given much thought to industry.
A newly minted MD, he was working at a hospital in Rio De Janeiro when one of his professors asked if he might take on a case that required consistent follow-up: A 14-year-old boy with Gaucher’s, a rare genetic disorder that meant he was missing a key enzyme often called the cell’s recycling system. He had come in with enlarged organs and stunted growth.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
